Lycera Corp., a biopharmaceutical company, develops oral immune modulators for the treatment of patients with autoimmune diseases and cancer. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.
2800 Plymouth Road
Ann Arbor, MI 48109
Founded in 2006
Lycera Corp. Announces Initiation of Phase 1/2a Study Argon of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors
Jan 4 17
Lycera Corp. announced the initiation of a Phase 1/2a clinical trial of the company's novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. The ARGON trial (Trial of RORgamma Agonist LYC-55716 in Advanced Cancer) is a Phase 1/2a study of LYC-55716 in patients with advanced, relapsed or refractory solid tumors. The initial Phase 1 portion of the study is designed to find the biologically active or maximum tolerated dose of LYC-55716. The study will utilize a 3+3 study design, in which LYC-55716 will be administered orally in subjects with relapsed or refractory solid tumors. The primary endpoints are safety and tolerability, and the study is designed to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose. Upon dose determination, LYC-55716 will enter Phase 2a, which is expected to enroll approximately 40 patients. The primary efficacy endpoint of the Phase 2a portion of the study will be objective response rate according to response evaluation criteria in solid tumors.
Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis
Dec 7 16
Lycera Corp. announced the initiation of a Phase 2 clinical trial of the Company's lead therapeutic candidate, LYC-30937-Enteric Coated, in patients with psoriasis. Psoriasis is often a debilitating skin disease that is estimated to affect as many as 7.5 million people in the United States, with approximately 1.5 - 3 million cases being diagnosed as moderate. Current systemic therapeutics for the treatment of moderate-to-severe psoriasis result in 75% improvement in the Psoriasis Area Severity Index (PASI) in approximately 80% of patients, but require injections and often lead to side effects, including pronounced immune suppression. A significant need exists for more convenient, orally dosed psoriasis treatments that provide high PASI scores and low rates of adverse events. Lycera's Phase 2 study UPRISE (gUt-directed LYC-30937-EC study in Psoriasis as oRal treatment for autoImmune diseaSE) is a randomized, double-blind, placebo-controlled parallel group trial designed to assess the efficacy and safety of LYC-30937-EC given orally once daily in subjects with moderate psoriasis. The study is expected to enroll up to 30 patients, randomized on a 2:1 basis to receive either treatment with LYC-30937-EC or placebo. Subjects will be treated for 12 weeks, with an additional 2-week safety follow-up. The primary efficacy endpoint will be the change in mean PASI Score and Investigator global assessment; safety will be measured over 14 weeks.
Lycera Corp. Appoints Scientific Advisory Board Members
Nov 10 16
Lycera Corp. announced the expansion of its scientific advisory board (SAB) to include 11 renowned clinical researchers and scientists. The company, which recently announced the initiation of its Phase 2 clinical trial of therapeutic candidate, LYC-30937-EC in patients with ulcerative colitis, is advancing a broad R&D pipeline of novel, oral immune modulators for the treatment of autoimmune diseases and cancer. Members of Lycera's scientific advisory board are focused on key aspects of biology, chemistry and clinical practice: Harinder Singh, PhD, (Chair), Director of the Division of Immunobiology and the Center for Systems Immunology, Cincinnati Children's Hospital Medical Center, Jonathan A. Ellman, PhD, Eugene Higgins Professor of Chemistry and Professor of Pharmacology, Yale University, Sarah Gaffen, PhD, Gerald P. Rodnan Professor of Rheumatology, University of Pittsburgh, Adrian Hayday, PhD, FRS, Kay Glendinning Professor of Immunobiology, King's College London, John McCall, PhD, Consultant, PharMac LLC, Eliot H. Ohlstein, PhD, Chief Scientific Officer, Velicept Therapeutics; Adjunct Professor of Pharmacology, Drexel University Medical School, Sarah J. Schlesinger, MD, Associate Professor of Clinical Investigation, The Rockefeller University; Clinical Director, The Laboratory of Molecular Immunology; Senior Physician, The Rockefeller University Hospital, Mario Sznol, MD, Professor of Internal Medicine, Deputy Section Chief, Medical Oncology, and Leader, Melanoma Translational Working Group, Yale University School of Medicine; Co-Director, Yale SPORE in Skin Cancer, Laurence A. Turka, MD, Co-director, Center for Transplantation Sciences, Massachusetts General Hospital; Harold and Ellen Danser Professor of Surgery, Harvard Medical School; Deputy Director, Immune Tolerance Network, Michael E. Weinblatt, MD, Co-director, Clinical Rheumatology, Brigham and Women's Hospital; John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School and Peter Wipf, PhD, Distinguished University Professor of Chemistry and Professor of Pharmaceutical Sciences, University of Pittsburgh; Co-Leader, UPCI Cancer Therapeutics Program.